Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma

T regulatory cells (Treg) avert autoimmunity, but their increased levels in melanoma confer a poor prognosis. To explore the basis for Treg accumulation in melanoma, we evaluated chemokine expression in patients. A 5-fold increase was documented in the Treg chemoattractants CCL22 and CCL1 in melanom...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2016-11, Vol.76 (21), p.6230-6240
Main Authors: Klarquist, Jared, Tobin, Kristen, Farhangi Oskuei, Peyman, Henning, Steven W, Fernandez, Manuel F, Dellacecca, Emilia R, Navarro, Flor C, Eby, Jonathan M, Chatterjee, Shilpak, Mehrotra, Shikhar, Clark, Joseph I, Le Poole, I Caroline
Format: Article
Language:English
Subjects:
Animals
Cell Proliferation
Chemokine CCL22 - physiology
Humans
Melanoma - pathology
Melanoma - therapy
Mice
Mice, Inbred C57BL
Receptors, CCR4 - physiology
Skin - immunology
T-Lymphocytes, Regulatory - physiology
Vaccination
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:T regulatory cells (Treg) avert autoimmunity, but their increased levels in melanoma confer a poor prognosis. To explore the basis for Treg accumulation in melanoma, we evaluated chemokine expression in patients. A 5-fold increase was documented in the Treg chemoattractants CCL22 and CCL1 in melanoma-affected skin versus unaffected skin, as accompanied by infiltrating FoxP3 T cells. In parallel, there was an approximately two-fold enhancement in expression of CCR4 in circulating Treg but not T effector cells. We hypothesized that redirecting Treg away from tumors might suppress autoimmune side effects caused by immune checkpoint therapeutics now used widely in the clinic. In assessing this hypothesis, we observed a marked increase in skin Treg in mice vaccinated with Ccl22, with repetitive vaccination sufficient to limit Treg accumulation and melanoma growth in the lungs of animals challenged by tumor cell injection, whether using a prevention or treatment protocol design. The observed change in Treg accumulation in this setting could not be explained by Treg conversion. Overall, our findings offered a preclinical proof of concept for the potential use of CCL22 delivered by local injection as a strategy to enhance the efficacious response to immune checkpoint therapy while suppressing its autoimmune side effects. Cancer Res; 76(21); 6230-40. ©2016 AACR.
ISSN:0008-5472
1538-7445
DOI:10.1158/0008-5472.CAN-16-0618